Maiwei Biopharma and Junshi Biopharma signed supplementary terms of the cooperation agreement on adalimumab injection
March 31, 2025
Source: drugdu
49
On March 27, Maiwei Biopharma (688062) issued an announcement that on March 26, 2025, the company and its wholly-owned subsidiaries signed a supplementary agreement on the cooperative development agreement on adalimumab injection with Junshi Biopharma and its wholly-owned subsidiaries.
Specifically, the company is responsible for the promotion of Junmaikang® and enjoys domestic sales rights at 60% of the net sales and shipment revenue, while Junshi Biopharma is responsible for production and enjoys 40% of the rights. In addition, the two parties share domestic R&D expenses and international sales rights at a ratio of 50%:50%.
In the first three quarters of 2024, Maiwei Biopharma achieved revenue of 141 million yuan and a net profit attributable to the parent of -694 million yuan.
https://finance.eastmoney.com/a/202503273358105290.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- 6 domestic ADCs successfully go global April 3, 2025
- Medical equipment giant begins layoffs and factory closures April 3, 2025
- Cultivate “Innovation Skills” and Cultivate “Conscience Seedlings” April 3, 2025
- Zhifei Biotech’s adjuvanted trivalent influenza vaccine has obtained clinical trial approval, which is expected to further enrich the company’s virus vaccine varieties April 3, 2025
- Under the vaccine price war, the performance of the leading influenza vaccine company Hualan Vaccine in 2024 has stalled April 3, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
